阿普米司特治疗儿童中重度斑块状银屑病:SPROUT随机对照试验52周结果
SPROUT为III期随机双盲安慰剂对照试验,245例6-17岁中重度斑块状银屑病患者按2:1随机接受阿普米司特或安慰剂16周,之后全部接受阿普米司特至52周。持续治疗下sPGA应答率从第16周30.1%升至第52周47.7%,PASI-75从42.3%升至60.4%,安慰剂转换组亦改善,未见新安全性信号。
要点
- 阿普米司特持续治疗52周,儿童中重度斑块状银屑病疗效持续改善。
- 第52周sPGA应答率达47.7%,PASI-75达60.4%。
- 安慰剂转换至阿普米司特后同样获得显著改善,安全性与已知特征一致。
核心结论
- 阿普米司特治疗儿童中重度斑块状银屑病52周疗效持续改善,安全性特征与已知一致。
研究设计与样本
- SPROUT为III期多中心随机双盲安慰剂对照平行组研究(NCT03701763),共随机245例6-17岁患者。
- 患者按2:1随机接受阿普米司特(体重20至<50 kg者20 mg,≥50 kg者30 mg)每日两次或安慰剂16周,之后全部接受阿普米司特至52周。
主要发现
- 阿普米司特/阿普米司特组sPGA应答率从第16周30.1%升至第52周47.7%。
- 安慰剂/阿普米司特组sPGA应答率从第16周9.8%升至第52周44.4%。
- 阿普米司特/阿普米司特组PASI-75从第16周42.3%升至第52周60.4%,安慰剂/阿普米司特组从13.4%升至63.9%。
- 第16至52周未观察到新的安全性信号。
关键数值与推荐
- sPGA应答定义为评分0或1且较基线下降≥2分。
- PASI-75定义为较基线改善≥75%。
临床怎么用
- 阿普米司特可作为儿童中重度斑块状银屑病口服治疗选择,52周持续获益且安全性可控。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oral treatment options for paediatric patients with moderate-to-severe plaque psoriasis are limited. In the 16-week double-blind placebo-controlled phase of the SPROUT trial, apremilast demonstrated efficacy vs. placebo in paediatric patients with psoriasis. OBJECTIVES: To evaluate the 52-week efficacy and safety of apremilast in SPROUT. METHODS: SPROUT was a phase III multicentre randomized double-blind placebo-controlled parallel-group study (NCT03701763). Patients were randomized 2 : 1 to receive apremilast 20 or 30 mg (for patients weighing 20 to < 50 kg or ≥ 50 kg at baseline, respectively) twice daily or placebo for 16 weeks, after which all patients received apremilast through week 52 (apremilast/apremilast or placebo/apremilast, respectively). Patients were aged 6-17 years and had moderate-to-severe psoriasis that was inadequately controlled by or intolerant to topical therapy. RESULTS: Of 245 patients randomized, 221 (apremilast/apremilast, n = 149; placebo/apremilast, n = 72) entered the apremilast extension phase and 186 (apremilast/apremilast, n = 125; placebo/apremilast, n = 61) completed 52 weeks. With continued apremilast treatment, rates of static Physician Global Assessment (sPGA) response (score of 0 or 1 with ≥ 2-point reduction from baseline) further improved from week 16 (30.1%) to week 52 (47.7%). In the placebo/apremilast group, sPGA response rates increased from 9.8% at week 16 to 44.4% at week 52. The proportions of patients with ≥ 75% reduction from baseline in Psoriasis Area and Severity Index increased from 42.3% at week 16 to 60.4% at week 52 in the apremilast/apremilast group and from 13.4% to 63.9% in the placebo/apremilast group. No new safety signals were observed. CONCLUSIONS: Improvements in clinical outcomes were sustained through 52 weeks with apremilast treatment in paediatric patients with moderate-to-severe psoriasis. Safety findings were consistent with the known safety profile. Psoriasis is a skin condition that causes red, scaly rashes, as well as itch and pain. It is estimated to affect around 125 million people worldwide. About 30% of cases of psoriasis develop in childhood. Many treatments approved for use in adults are not approved for children. In this multinational SPROUT study, we looked at how effective and safe an oral drug called ‘apremilast’ was in treating psoriasis in children and adolescents for over 1 year. Altogether, 245 patients were given either apremilast or ‘placebo’ (a dummy drug containing no active ingredients) for 16 weeks. After this, all patients received apremilast until week 52. We looked at how many patients developed clear or almost clear skin. We noted how many patients saw a decrease of at least 75% in the affected area and severity of their psoriasis. We also monitored patients’ safety during the study. Previous research showed that apremilast improved the symptoms of psoriasis symptoms after 16 weeks. In this study, we found that these treatment benefits were maintained for 1 year. They even continued to improve up to the end of the study. By week 52, almost half of the patients had clear or almost clear skin. More than half of patients experienced a reduction in their psoriasis by at least 75%. This was true whether they received apremilast from the beginning of the study or switched from the placebo to apremilast at week 16. We also found no new side effects from week 16 to week 52. In conclusion, our findings suggest that apremilast could improve psoriasis in children and adolescents over 1 year of treatment. There were no major safety concerns.
引用
- Paller AS, Fiorillo L, Becker E, et al. Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial. Br J Dermatol. 2025. PMID: 40737559. doi:10.1093/bjd/ljaf305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。